AngioDynamics, Inc. (ANGO) Shares Bought by Thomson Horstmann & Bryant Inc.

Thomson Horstmann & Bryant Inc. lifted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 1.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 373,313 shares of the medical instruments supplier’s stock after acquiring an additional 4,005 shares during the quarter. Thomson Horstmann & Bryant Inc. owned 1.01% of AngioDynamics worth $6,439,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. BlackRock Inc. increased its position in shares of AngioDynamics by 7.9% during the first quarter. BlackRock Inc. now owns 5,103,954 shares of the medical instruments supplier’s stock worth $88,045,000 after acquiring an additional 373,558 shares during the period. Wells Fargo & Company MN increased its position in shares of AngioDynamics by 6.7% during the first quarter. Wells Fargo & Company MN now owns 1,214,928 shares of the medical instruments supplier’s stock worth $20,957,000 after acquiring an additional 76,767 shares during the period. Royce & Associates LP increased its position in shares of AngioDynamics by 13.8% during the fourth quarter. Royce & Associates LP now owns 1,098,817 shares of the medical instruments supplier’s stock worth $18,273,000 after acquiring an additional 133,660 shares during the period. Fort Washington Investment Advisors Inc. OH increased its position in shares of AngioDynamics by 14.1% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 1,028,479 shares of the medical instruments supplier’s stock worth $17,741,000 after acquiring an additional 127,000 shares during the period. Finally, Fenimore Asset Management Inc. increased its position in shares of AngioDynamics by 0.6% during the fourth quarter. Fenimore Asset Management Inc. now owns 594,490 shares of the medical instruments supplier’s stock worth $9,886,000 after acquiring an additional 3,715 shares during the period. 97.62% of the stock is currently owned by institutional investors and hedge funds.

Shares of AngioDynamics opened at $20.54 on Friday, MarketBeat Ratings reports. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.88 and a quick ratio of 1.84. The firm has a market cap of $749.71 million, a P/E ratio of 28.14, a PEG ratio of 1.84 and a beta of 1.01. AngioDynamics, Inc. has a 12 month low of $14.97 and a 12 month high of $20.71.



AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, March 29th. The medical instruments supplier reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.05. The firm had revenue of $83.85 million during the quarter, compared to the consensus estimate of $86.13 million. AngioDynamics had a net margin of 0.97% and a return on equity of 5.11%. sell-side analysts anticipate that AngioDynamics, Inc. will post 0.74 earnings per share for the current year.

A number of analysts have recently weighed in on ANGO shares. Raymond James raised AngioDynamics from a “market perform” rating to an “outperform” rating and set a $16.33 price objective on the stock in a research report on Tuesday, April 3rd. UBS raised AngioDynamics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, April 3rd. BidaskClub raised AngioDynamics from a “sell” rating to a “hold” rating in a research report on Thursday, February 22nd. TheStreet raised AngioDynamics from a “c” rating to a “b-” rating in a research report on Monday, April 16th. Finally, Zacks Investment Research lowered AngioDynamics from a “buy” rating to a “hold” rating in a research report on Friday, January 26th. Five investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $17.87.

AngioDynamics Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply